肝窦阻塞综合征成功诊治1例报告

耿雯倩; 朱浩; 杨鑫; 李婉玉; 许芳; 蔡艳俊; 高普均

doi:10.3969/j.issn.1001-5256.2023.02.023

肝窦阻塞综合征成功诊治1例报告

DOI: 10.3969/j.issn.1001-5256.2023.02.023

吉林大学第一医院肝胆胰内科，长春 130000

基金项目:

吉林大学第一医院交叉学科创新项目 (JDYYJC006)

伦理学声明：本例报告已获得患者知情同意。

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：耿雯倩负责课题设计，资料分析，撰写论文；朱浩、杨鑫、许芳、蔡艳俊参与收集数据，修改论文；李婉玉、高普均负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
李婉玉，liwanyu@jlu.edu.cn (ORCID: 0000-0002-0706-7019)

计量
- 文章访问数: 866
- HTML全文浏览量: 383
- PDF下载量: 100
- 被引次数: 0
出版历程
- 收稿日期: 2022-06-10
- 录用日期: 2022-07-25
- 出版日期: 2023-02-20

A case report of successful diagnosis and treatment of hepatic sinusoidal obstruction syndrome

Department of Hepatology, The First Hospital of Jilin University, Changchun 130000, China

Research funding:

Interdisciplinary Innovation Project of the First Hospital of Jilin University (JDYYJC006)

More Information

Corresponding author: LI Wanyu, liwanyu@jlu.edu.cn (ORCID: 0000-0002-0706-7019)

摘要

- 肝静脉闭塞性疾病 /
- 土三七 /
- 诊断 /
- 治疗学
- Hepatic Veno-Occlusive Disease /
- Sedum Aizoon /
- Diagnosis /
- Therapeutics

HTML全文

图 1 肝胆胰多排CT平扫+三期增强

注：a、b为治疗前肝内静脉分支显示不清；c、d为治疗后肝内静脉可见显影(白色箭头所示)。

Figure 1. Hepatobiliary and pancreatic multi-slice CTplain scan+three-phase enhancement

下载: 全尺寸图片幻灯片

图 2 肝穿刺活检结果(HE染色，×200)

注：a，治疗前肝穿刺活检：肝腺泡结构紊乱，肝小叶中央静脉周围Ⅲ带及Ⅱ带肝窦高度扩张及淤血，Ⅲ带大部分肝细胞萎缩、消失；b，治疗后肝穿刺活检：肝腺泡结构大致维持正常，肝细胞弥漫水样变性，肝窦不规则扩张。

Figure 2. Liver biopsy results (HE staining, ×200)

下载: 全尺寸图片幻灯片

参考文献(13)

[1]	REN XF, ZHUGE YZ, CHEN SY, et al. Gynura segetum-related hepatic sinusoidai obstruction syndrome: a national multicenter clinical study[J]. Chin J Dig, 2017, 37(8): 523-529. DOI: 10.3760/cma.j.issn.0254-1432.2017.08.004. 任晓非, 诸葛宇征, 陈世耀, 等. 土三七相关肝窦阻塞综合征的全国多中心临床调研分析[J]. 中华消化杂志, 2017, 37(8): 523-529. DOI: 10.3760/cma.j.issn.0254-1432.2017.08.004.
[2]	LIU SS, ZHOU XD. Study on gynura segetum-induced hepatic sinusoidal obstruction syndrome[J]. J Clin Intern Med, 2020, 37(4): 256-259. DOI: 10.3969/j.issn.1001-9057. 2020.04.004. 刘少松, 周晓东. 吡咯烷生物碱诱导肝窦阻塞综合征的研究进展[J]. 临床内科杂志, 2020, 37(4): 256-259. DOI: 10.3969/j.issn.1001-9057. 2020.04.004.
[3]	Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003. 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
[4]	XIAO J, TU J, ZHANG H, et al. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt[J]. Hepatol Int, 2021, 15(3): 720-729. DOI: 10.1007/s12072-020-10126-x.
[5]	WANG JY, GAO H. Tusanqi and hepatic sinusoidal obstruction syndrome[J]. J Dig Dis, 2014, 15(3): 105-107. DOI: 10.1111/1751-2980.12112.
[6]	WANG LL, SUN J. Advances in diagnosis and treatment of hepatic sinus obstruction syndrome caused by pyrrole alkaloids[J]. Int J Dig Dis, 2020, 40(2): 96-99. DOI: 10.3969/j.issn. 1673-534X.2020.02.008. 王露露, 孙璟. 吡咯生物碱导致的肝窦阻塞综合征的诊治进展[J]. 国际消化病杂志, 2020, 40(2): 96-99. DOI: 10.3969/j.issn. 1673-534X.2020.02.008.
[7]	LIU ZL, FAN ZP, GOU YS. Clinical features, pathogenesis, and diagnosis and treatment of different types of hepatic sinusoidal obstruction syndrome[J]. J Clin Hepatol, 2019, 35(1): 208-212. DOI: 10.3969/j.issn.1001-5256.2019.01.046. 刘贞利, 范作鹏, 勾钰淞, 等. 不同类型肝窦阻塞综合征的临床特征、发病机制与诊治[J]. 临床肝胆病杂志, 2019, 35(1): 208-212. DOI: 10.3969/j.issn.1001-5256.2019.01.046.
[8]	DIGNAN FL, WYNN RF, HADZIC N, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J]. Br J Haematol, 2013, 163(4): 444-457. DOI: 10.1111/bjh.12558.
[9]	MOHTY M, MALARD F, ABECASSIS M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)[J]. Bone Marrow Transplant, 2015, 50(6): 781-789. DOI: 10.1038/bmt.2015.52.
[10]	LI SY, WANG Y. Progress in the pathogenesis, clinical diagnosis and treatment of hepatic sinus obstruction syndrome induced by Tuanqi[J]. Chin Hepatol, 2018, 23(6): 540-542. DOI: 10.3969/j.issn.1008-1704.2018.06.027. 李世英, 汪艳. 土三七致肝窦阻塞综合征的发生机制与临床诊治研究进展[J]. 肝脏, 2018, 23(6): 540-542. DOI: 10.3969/j.issn.1008-1704.2018.06.027.
[11]	LIU Z, JI SL, WANG FS. Research progress of the pharmacological effects and clinical applications of low molecular weight heparins[J]. Pharm Biotech, 2014, 21(6): 573-578. DOI: 10.19526/j.cnki.1005-8915.2014.06.020.
[12]	Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Expert consensus on TCM diagnosis and treatment of ascites due to cirrhosis (2017)[J]. J Clin Hepatol, 2017, 33(9): 1621-1626. DOI: 10.3969/j.issn.1001-5256.2017.09.002. 中华中医药学会脾胃病分会. 肝硬化腹水中医诊疗专家共识意见(2017)[J]. 临床肝胆病杂志, 2017, 33(9): 1621-1626. DOI: 10.3969/j.issn.1001-5256.2017.09.002.
[13]	JIANG MJ, SONG LS, XIN GJ, et al. Low-molecular-weight heparin sodium for the treatment of hepatic sinusoidal obstruction syndrome: A case report[J]. J Clin Hepatol, 2019, 35(7): 1594-1595. DOI: 10.3969/j.issn.1001-5256.2019.07.035. 姜敏杰, 宋立莎, 辛桂杰, 等. 低分子肝素钠治疗肝窦阻塞综合征1例报告[J]. 临床肝胆病杂志, 2019, 35(7): 1594-1595. DOI: 10.3969/j.issn.1001-5256.2019.07.035.